ARS Pharmaceuticals (SPRY) EBT Growth (3y) (2023 - 2026)
ARS Pharmaceuticals (SPRY) EBT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 86.16% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 41.79% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 95.61% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 38.36% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 64.03% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 86.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.37% |
| Mar 31, 2026 | 86.55% |
| Dec 31, 2025 | -42.20% |
| Sep 30, 2025 | -95.35% |
| Jun 30, 2025 | -154.18% |
| Mar 31, 2025 | -47.65% |
| Dec 31, 2024 | 0.05% |
| Sep 30, 2024 | -51.81% |
| Jun 30, 2024 | 22.70% |
| Mar 31, 2024 | -67.61% |
| Dec 31, 2023 | 9.49% |
| Sep 30, 2023 | -1,120.29% |
| Jun 30, 2023 | -1,673.18% |
| Mar 31, 2023 | -1,811.87% |